Biology of radionuclide therapy

proceedings of a symposium held at Loews L"Enfant Plaza Hotel, Washington, D.C., September 29 & 30, 1988

Publisher: American College of Nuclear Physicians in Washington, D.C

Written in English
Published: Pages: 284 Downloads: 642
Share This

Subjects:

  • Radioisotope brachytherapy -- Congresses.,
  • Cancer -- Radiotherapy -- Congresses.

Edition Notes

Statementeditor, Gerald L. DeNardo ; associate editors, Jerry P. Lewis, Antolin Raventos, Robert W. Burt.
SeriesFrontiers in nuclear medicine series ;, 2
ContributionsDeNardo, Gerald L., 1932-, United States. Dept. of Energy. Office of Health and Environmental Research.
Classifications
LC ClassificationsRC271.R27 B56 1989
The Physical Object
Paginationxi, 284 p. :
Number of Pages284
ID Numbers
Open LibraryOL2198358M
LC Control Number89018129

This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future :// The title of this book “Targeted Radionuclide Tumour Therapy – Biological Aspects” was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have ?pid=diva Most neuroendocrine tumors have five highly specialized receptors that bind to the naturally occurring hormone somatostatin. Peptide receptor radionuclide therapy (PRRT) combines compounds capable of attaching to receptors with a radionuclide such as Lu. These can then be administered, and will circulate throughout the body, binding to the tumor cells which have receptors for ://   《Gene Therapy—Principles and Applications 》 99年版的《Gene Therapy—Principles and Applications 》基因治疗—原理与应用。 分子克隆实验指南(第二版) 页的经典图书,需要安装超星图书阅览器才能查看。

  Praise for The Biology of Belief “Bruce Lipton’s book is the definitive summary of the new biology and all it implies. It is magnificent, profound beyond words, and a delight to read. It synthesizes an encyclopedia of critical new infor - mation into a brilliant yet simple package. These pages contain a   7 Biology, McMaster University, Main St. W., Hamilton, Ontario L8S 4M1, Canada 8 15 demand for cancer imaging and radionuclide therapy applications. The synthesis, 16 characterization, and in vivo evaluation of radioiodinated triazoles designed as probes to target   Capello A, Krenning EP, Breeman WA, et al. Peptide receptor radionuclide therapy in vitro using [ In-DTPA0]octreotide. J Nucl Med. ; Google Scholar: van der Zwan WA, Bodei L, Mueller-Brand J, et al. GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. ; R1-R8. Google Scholar: Cives M About this book. An Introduction to Molecular Medicine and Gene Therapy Edited by Thomas F. Kresina, Ph.D. Gene therapy, or the use of genetic manipulation for disease treatment, is derived from advances in genetics, molecular biology, clinical medicine, and human genomics. Molecular medicine, the application of molecular biological techniques

  targeted radionuclide therapy listen (TAR-geh-ted RAY-dee-oh-NOO-klide THAYR-uh-pee) A type of radiation therapy in which a radionuclide (a radioactive chemical) is linked to a cell-targeting molecule, such as a monoclonal antibody, and injected into the ://   It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future  › Home › eBooks.   Peptide receptor radionuclide therapy (PRRT) with Lutetium ( Lu) -DOTATATE is effective treatment for neuroendocrine tumors (NETs). Dosimetry assessment can be used to maximize the tumour dose, while keeping the dose delivered to critical organs to acceptable ://

Biology of radionuclide therapy Download PDF EPUB FB2

The recent revolution in molecular biology offers exciting new opportunities for targeted radionuclide therapy. This up-to-date, comprehensive book, written by world-renowned experts, discusses the basic principles of radionuclide therapy, explores in detail the available treatments, explains the regulatory requirements, and examines likely future  › Medicine › Radiology.

The book is divided into 5 sections: Immunology and Targeting Constructs, The Science of Targeted Radionuclide Therapy, Tumor Microenvironment and Delivery Strategies, Uncojugated Therapy, Conjugated Therpy. The clinical aspect of this promising therapy is thoroughly  › Books › New, Used & Rental Textbooks › Medicine & Health Sciences.

The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and  › Books › New, Used & Rental Textbooks › Medicine & Health Sciences.

The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation.

Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and  › Biomedical Sciences › Cancer Research.

Oncology Book ofBritish Medical Association's Medical Book Awards. Awarded first prize in the Oncology category at the BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments.

Expert discussion covers a range of diverse topics associated with this field, including   These findings may have implications for targeted radionuclide therapy because if RIBBE could be harnessed, it could help compensate for variability in radiation dose deposition which is the bane of targeted radionuclide therapy (O’Donoghue et al.

Recent advances in molecular biology, radiopharmaceutical chemistry and radioisotope production have stimulated a new era for the use of radiopharmaceuticals for targeted radionuclide therapy (TRT /_Targeted_Radionuclide_Therapy_-_An_Overview.

Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Western civilization.

Although localized prostate cancer can be treated effectively in different ways, almost all patients progress to the incurable metastatic castration-resistant prostate cancer. Due to the significant mortality and morbidity rate associated with the The discipline of nuclear medicine consists of radionuclide imaging and radionuclide therapy with the number of patients having radionuclide imaging studies being much greater than those who have radionuclide therapy.

The use of radionuclide imaging and therapeutic procedures is increasing because they have an important role in the management of patients with ://   Peptide Receptor Radionuclide Therapy (PRRNT) using Yttrium DOTATOC was first The book covers clinical presentations, elegibility criteria, and means of assessing It provides theoretical and practical knowledge on the biology, indications, diagnosis, and current therapeutic options for the treatment of Description: The recent revolution in molecular biology offers exciting new opportunities for targeted radionuclide therapy.

This up-to-date, comprehensive book, written by world-renowned experts, discusses the basic principles of radionuclide therapy, explores in detail the available treatments, explains the regulatory requirements, and   A radionuclide (radioactive nuclide, radioisotope or radioactive isotope) is an atom that has excess nuclear energy, making it unstable.

This excess energy can be used in one of three ways: emitted from the nucleus as gamma radiation; transferred to one of its electrons to release it as a conversion electron; or used to create and emit a new particle (alpha particle or beta particle) from the   IAEA Publications Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours This book provides consensus guidance on the use of Peptide Receptor Radionuclide Therapy (PRRNT) for the treatment of neuroendocrine :// Content is templated and divided into three sections --Scientific Foundations of Radiation Oncology, Techniques and Modalities, and Disease Sites – for quick access to e Sites chapters summarize the most important issues on the opening page and include a full-color format, liberal use of tables and figures, a closing section with a discussion of controversies and problems Radiation biology and radiation dosimetry are then addressed, with the inclusion of a chapter specifically devoted to biology and dosimetry for the lens of the eye.

Discussion of radiation doses to patients and to embryos, fetuses, and children forms a central part of the :// The systemic radionuclide therapy has gained full consideration, with its efficacy being widely accepted. It offers the prospective of pain relief with negligible side effects. Recently, it has been also implemented in combination with other therapeutic :// Radionuclide Peptide Cancer Therapy - CRC Press Book Offering lower toxicity and higher accuracy than conventional therapies, this source offers illustrative coverage of this new method to treat tumors associated with brain, breast, lung, and neuroendocrine :// Targeted radionuclide therapy of hematopoietic malignancies in the clinical setting has been achieved and similar successes with solid tumors and cells disseminated from them are likely within ://   The potential use of radionuclides in therapy has been recognized for many decades.

A number of radionuclides, such as iodine ( I), phosphorous (32 P), strontium (90 Sr), and yttrium (90 Y), have been used successfully for the treatment of many benign and malignant ly, the rapid growth of this branch of nuclear medicine has been stimulated by the For treatment of systemic malignancies, when external radiation therapy is not applicable, radionuclide therapy can be an alternative.

In this form of therapy, radionuclides are administered to the patient, often in a form where the radionuclide is labelled to a molecule that plays the active part in the localization of the tumor. Since the aim is to impart lethal damage to tumor cells while It is a topic rapidly increasing in importance and success in treatment of cancer patients.

This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future :// First Prize winner, Oncology Book Category, British Medical Association Medical Book Competition Key Features Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets.

It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for The Selection, Use, Calibration, and Quality Assurance of Radionuclide Calibrators Used in Nuclear Medicine: Report TG Quality assurance for image-guided radiation therapy utilizing CT-based technologies: A report of the AAPM TG Report TG The Use and QA of Biologically Related Models for Treatment Planning: Report   Title: Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy VOLUME: 7 ISSUE: 4 Author(s):Bart Cornelissen and Katherine A Vallis Affiliation:MRC/CRUK Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, OX3 7LJ, United Kingdom.

Keywords:Auger-electron, radionuclide, radioimmunotherapy, nucleus, targeted radiotherapy, The title of this book “Targeted Radionuclide Tumor Therapy – Biological aspects” was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation.

Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization   Advancing Nuclear Medicine Through Innovation highlights the exciting emerging opportunities in nuclear medicine, which include assessing the efficacy of new drugs in development, individualizing treatment to the patient, and understanding the biology of human diseases.

Health care and pharmaceutical professionals will be most interested in ICRTThe 14th International Conference on the Radiopharmaceutical Therapy (ICRT) will be held in Nanjing from August 21 to 24, This conference will offer to our Chinese and International Colleagues a unique opportunity to learn about the recent advances   A simplified yet comprehensive overview on oncological malignancies, their biology, diagnosis, staging, treatment and follow-up, which are necessary for basic patient treatment Handbooks ESMO members: the recent ESMO Handbooks are available for browsing online to allow you to easily access the sections most relevant to :// /Peptide-Receptor-Radionuclide-Therapy-PRRT2.

Search the world's most comprehensive index of full-text books. My library. Receptor Radionuclide Therapy: From 90Y to Lu Labeled Peptides. Therapeutic Potential of Radiolabeled Peptides with Beta and Alpha Emitters. Receptor-Mediated Radionuclide Therapy: The European Institute of Oncology Experience.

DOSIMETRIC ASPECTS AND REGULATORY REQUIREMENTS. Radiation Dosimetry in Preparation to ://Get this from a library! Targeted radionuclide therapy. [Tod W Speer;] -- "Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets.

It is a topic rapidly   This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the ://